A PYMNTS Company

First of All, Do No Harm: New Directions in EU Antitrust Enforcement Regarding Pharmaceuticals

BY | May 11, 2020

The recent Paroxetine and CMA v. Pfizer/Flynn cases confirm the EU approach to pay-for-delay, respectively establish a workable approach to excessive pharmaceutical pricing at least regarding non-innovative drugs. This enables…

The recent Paroxetine and CMA v. Pfizer/Flynn cases confirm the EU approach to pay-for-delay, respectively establish a workable approach to excessive pharmaceutical pricing at least regarding non-innovative drugs. This enables antitrust consolidation regarding further such cases. New directions in the application of EU antitrust law to the pharmaceutical sector can now be identified as a next step. These include an increased focus on biosimilars, the pursuit of excessive pricing cases where paten

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.222.189.51

Please verify email or join us to access premium content!